Taiwan develops high potent immunotherapy for COVID-19 Omicron variant
AcadeMab's cutting-edge technology using Single B cell technology will benefit high-risk people who are moderate to severely immunocompromised and lack adequate immunity responses despite COVID-19 vaccinations.
Source: biospectrumasia.com